Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Udvardy Miklos, Vladimir Strugov, MD, Catharina Lewerin, MD PhD, Sebastian Grosicki, MD PhD, Grzegorz Mazur, MD PhD, Michael Steurer, MD, Marco Montillo, MD, Irina Kryachok, Prof., PhD, Jan Moritz Middeke, MD, Grygoriy Rekhtman, MD, Tommaso Stefanelli, Ghislaine Vincent, Sameera G, PhD, Anders Österborg, MD PhD Prof.

Blood (2018) 132 (Supplement 1): 5569.

https://doi.org/10.1182/blood-2018-99-113295

Published: 2018

Journal Articles

Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)

Francesco Rodeghiero, Andrew Provan, Michael Steurer, MD, Bertrand Godeau, MD, Nancy Carpenter, MSc, Georg Kreuzbauer, MD

Blood (2014) 124 (21): 4199.

https://doi.org/10.1182/blood.V124.21.4199.4199

Published: 2014

Journal Articles

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Michael Steurer, MD, Marco Montillo, MD, Lydia Scarfò, Francesca Romana Mauro, Johannes Andel, MD, Sophie Wildner, MD, Livio Trentin, MD, Ann Janssens, MD, Sonja Burgstaller, MD, Anna Kruschinski, PhD, Thomas Dümmler, PhD, Kai Riecke, MD, Paolo Ghia, MD PhD, Federico Caligaris-Cappio, MD, Marco Gobbi, MD

Blood (2014) 124 (21): 1996.

https://doi.org/10.1182/blood.V124.21.1996.1996

Published: 2014

Journal Articles

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Blood (2014) 124 (21): 20.

https://doi.org/10.1182/blood.V124.21.20.20

Published: 2014

Journal Articles

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Marco Gobbi, MD, Michael Steurer, MD, Federico Caligaris-Cappio, MD, Marco Montillo, MD, Ann Janssens, MD, Livio Trentin, MD, Thomas Dümmler, PhD, Stefan Zöllner, PhD, Stefan Zeitler, MD, Kai Riecke, MD, Anna Kruschinski, PhD

Blood (2013) 122 (21): 1635.

https://doi.org/10.1182/blood.V122.21.1635.1635

Published: 2013

Journal Articles

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

Alexander Egle, Michael Steurer, MD, Franz Josef Gassner, PhD, Roland Geisberger, Thomas Melchardt, MD, Lisa Pleyer, MD, DI, Lukas Weiss, MD, Michael A. Fridrik, MD, Josef Thaler, MD, Alois Lang, MD, Richard Greil, MD

Blood (2013) 122 (21): 4164.

https://doi.org/10.1182/blood.V122.21.4164.4164

Published: 2013

Journal Articles

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood (2013) 122 (21): 368.

https://doi.org/10.1182/blood.V122.21.368.368

Published: 2013

Journal Articles

Blood Cells Dynamic and Thrombo-Haemorragic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.

Blood (2012) 120 (21): 2839.

https://doi.org/10.1182/blood.V120.21.2839.2839

Published: 2012

Journal Articles

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Dominik Selleslag, Ann Janssens, Hans Wadenvik, Michael Steurer, MD, Philippe Quittet, MD, Georgia Kaiafa, Tomas Kozak, MD, Helen Papadaki, Jean-François Viallard, MD, PhD, Kerry Dillingham, Georg Kreuzbauer, MD

Blood (2012) 120 (21): 3316.

https://doi.org/10.1182/blood.V120.21.3316.3316

Published: 2012

Journal Articles

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

Ann Janssens, MD, Michael D. Tarantino, MD, Robert Bird, MD, Maria Gabriella Mazzucconi, MD, Ralph Vincent V. Boccia, MD, Maria Fernanda Lopez-Fernandez, MD, Tomas Kozak, MD, Michael Steurer, MD, Peter A.W. Te Boekhorst, MD, PhD, Kerry Dillingham, MSc, Richard Lizambri, MD

Blood (2011) 118 (21): 3279.

https://doi.org/10.1182/blood.V118.21.3279.3279

Published: 2011

Journal Articles

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

Alexander Egle, MD, Michael Steurer, MD, Franz Gassner, Roland Geisberger, PhD, Thomas Melchardt, MD, Lukas Weiss, MD, Michael A. Fridrik, MD, Josef Thaler, MD, Alois Lang, MD, Richard Greil, MD

Blood (2011) 118 (21): 292.

https://doi.org/10.1182/blood.V118.21.292.292

Published: 2011

Journal Articles

GRP-78 Secreted by Tumor Cells Blocks the Anti-Angiogenic Activity of Bortezomib.

Johann Kern, Gerold Untergasser, PhD, Christoph Zenzmaier, Bettina Sarg, Gunther Gastl, Prof., Dr., Eberhard Gunsilius, M.D., Michael Steurer, MD

Blood (2009) 114 (22): 4805.

https://doi.org/10.1182/blood.V114.22.4805.4805

Published: 2009

Journal Articles

The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis.

Alexander Egle, MD, Michael Steurer, MD, Thomas Melchardt, Marion Stoll, Richard Greil

Blood (2009) 114 (22): 3453.

https://doi.org/10.1182/blood.V114.22.3453.3453

Published: 2009

Journal Articles

Anti-Angiogenic Activity of Bortezomib Is blocked by a 50–60 KDa Protein Secreted by Various tumor Cell Lines

Johann Kern, Gerold Untergasser, PhD, Heinz Zoller, MD, Gunther Gastl, Eberhard Gunsilius, M.D., Michael Steurer, MD

Blood (2008) 112 (11): 5448.

https://doi.org/10.1182/blood.V112.11.5448.5448

Published: 2008

NARROW

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Pooled Analysis of Safety and Efficacy of Romiplostim in Splenectomized and Nonsplenectomized Patients (pts) with Immune Thrombocytopenia (ITP)

Results from a Phase IIa Study of the Anti-CXCL12 Spiegelmer Olaptesed Pegol (NOX-A12) in Combination with Bendamustine/Rituximab in Patients with Chronic Lymphocytic Leukemia

Rituximab Maintenance after Chemoimmunotherapy Induction in 1 st and 2 nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial

Anti-CXCL12/SDF-1 Spiegelmer ® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Blood Cells Dynamic and Thrombo-Haemorragic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.

Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice – Interim Results From a Large, European, Observational Study

Final Results from an International, Multi-Center, Single-Arm Study Evaluating the Safety and Efficacy of Romiplostim in Adults with Primary Immune Thrombocytopenia (ITP),

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

GRP-78 Secreted by Tumor Cells Blocks the Anti-Angiogenic Activity of Bortezomib.

The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis.

Anti-Angiogenic Activity of Bortezomib Is blocked by a 50–60 KDa Protein Secreted by Various tumor Cell Lines

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only